Baidu
map

Nature Medicine:持续的行为改变是预防和应对未来流行病的关键

2021-05-12 MedSci原创 MedSci原创

为了应对COVID-19和未来大流行带来的持续威胁,需要对研究和项目进行投资,以发现和应用为持续行为改变奠定基础的原则,这将需要行为、社会、生物医学、公共卫生和临床科学家之间的合作。

为了应对COVID-19和未来大流行带来的持续威胁,需要对研究和项目进行投资,以发现和应用为持续行为改变奠定基础的原则,这将需要行为、社会、生物医学、公共卫生和临床科学家之间的合作。人类行为在导致COVID-19的过程中起了重要作用,改变它对于应对这场大流行至关重要。

在减轻COVID-19对健康和经济的危害方面做得最好的国家迅速并成功地说服其民众进行大规模的行为改变。这些干预措施中,有些非常有效,有些则不那么有效,有些造成了重大的社会和财政伤害。特别是,国家的"封锁"有效地阻止了人们相互接触,减少了疾病的传播,但它们对人们的生活和国民经济造成了极大的损害。因此,在理想情况下,封锁应仅用于将传播水平降低到其他政策可以控制的程度。这些策略包括充分的“查找、检测、跟踪、隔离和支持”系统,边境控制和检疫,以防止重新播种感染,创造安全的工作、家庭和交通空间,以及个人保护行为的推广,如使用口罩。

能力,机会和动力

需要大规模、持续的行为改变,以减少未来大流行的风险,并为之做好准备。COVID-19大流行表明,在特定条件下,人们至少会采取一些必要的行为。然而,不同国家、不同时期和不同社会群体的情况各不相同。要实现持续的行为变化,决策者和干预设计师必须充分理解是什么支撑了相关的行为。例如,在所有文化中,如何确保人们在适当的情况下保持安全的身体距离、戴口罩和消毒双手?需要什么措施来确保在封闭的空间中提供足够的通风,以及在高风险环境中的人们有效地使用个人防护设备?

Michie, S.West, R提供了预防和缓解流行病等的重要行为目标。

一个简单、全面的理解行为的方法是通过“能力-机会-动机-行为”(COM-B)模型。

该模型的前提是,任何行为的发生,人必须具备以下条件:相关的身体和心理能力;机会;他们会有更大的动机去做这个行为,而不是做其他任何事情。能力和机会会转化为动机,所以有更大的能力和机会可以增加动机,行为随后会反馈,因此改变行为可以反过来影响能力、机会和/或动机。因此,行为是进化和互动系统的一部分。创造持续的行为改变需要改变能力,机会和动机,这些是相互加强的。

能力、机会和动机对任何行为的发生都是必不可少的。能力和机会影响动机,行为反馈影响能力、机会和动机。身体能力包括力量、耐力、身体和精神运动技能,而心理能力包括知识、复原力和心理技能。动机既包括反思过程(如自我意识决策),也包括涉及情感和习惯的自动过程。机会包括拥有资源、时间和物理空间来实施一种行为,它还包括让行为成为可能或促进行为的社会结构、规范和线索。世界卫生组织利用COM-B模式提出建议,以提高对防范COVID-19行为的规则和指导的遵守程度。

行为改变的需求

开发有效的干预措施需要了解在能力、动机或机会,或它们的组合方面的什么变化将推动行为的改变。错误的平衡可能是灾难性的。例如,在2020年,英国政府在必要时让COVID-19患者自我隔离的努力基本上失败了,部分原因是它没有吸取这一教训。调查数据显示,不到50%的COVID-19症状患者报告在家中进行了必要的隔离。没有自我隔离似乎很大程度上是由于经济需求、家庭或照顾孩子的责任-例如缺乏机会。在需要的时候,低收入者和那些有更多经济资源的人一样有自我隔离的动机,但低收入者的自我隔离程度更低。最容易被隔离的人是那些可以在大房子里工作、有资金订餐和其他服务的人。充分的财政和实际支助本应是解决办法的一个关键部分,它是许多国家有效控制大流行的基础,可报销高达100%的工资损失,并提供免费的替代住宿和每日探视。在美国,在一些司法管辖区,为有症状或必须隔离的人引入紧急法定病假的权利在减少病例方面是有效的。

英国政府似乎错误地认为,人们不隔离的主要原因是缺乏动机,而不是缺乏机会。如果不遵守隔离规定,将被处以1万英镑的罚款。一项在利物浦市进行的免费大规模检测的评估发现,在一些地区,弱势群体接受诊断性检测的比例低至4%。据估计,价值360亿英镑的检测、追踪和隔离系统只覆盖了COVID-19检测呈阳性的人的3%似乎巨额罚款的威胁确实产生了动机上的影响,但它与本意相反,避免罚款的最好办法是避免考试。

行为改变轮

上述英国案例研究表明,要实现大规模行为改变的预期结果,系统的方法需要从理解行为的背景转移到确定可以改变行为的干预措施和政策。一个这样的框架是行为改变轮,通过整合文献综述中确定的19个框架而发展出来。这个轮可以用来将COM-B模型与9种可能的干预类型和7种可供实施的政策选项联系起来。

设计干预措施的行为改变轮框架

干预设计人员可以使用该轮识别最有可能实现预期变化的干预类型,然后根据可能存在的限制因素,选择最合适的实施方案组合。让医务人员遵守感染预防和控制指南的挑战可以说明行为改变轮框架的使用。一项已发表的研究确定了一系列可能有效的干预措施,但重要的是要走得更远,考虑在特定背景下需要解决的能力、机会和动机问题。

首先,就能力而言,有指导方针的性质,它们如何沟通以及为此需要什么培训。第二,在机会的背景下,考虑员工工作的物理空间和他们从管理者那里得到的支持是至关重要的。第三,为了激励工作人员,重要的是要让工作人员相信他们的个人防护设备,并且在需要时使用起来舒适。最后,为了充分处理能力、机会和动机问题,必须让所有工作人员,包括支助工作人员,参与制订和执行干预措施的过程。这项研究的结果进一步说明了需要将所有的演员和行为在一个给定的场景作为一个相互联系的系统的一部分,并指出工作场所文化作为一个重要的影响,特别是管理者和同行的支持,社会规范团结和注重安全而不是自满。

领导力、信任和团结

说到坚持严格的大流行控制法规的动力,不同国家的做法存在差异,这凸显了良好的领导力对培养公众对政府和专家的信任以及团结意识的重要性。信任来自于人们将权威视为社区的一部分并为社区服务,而这反过来又来自于这些权威将公众视为受尊重的伙伴而不是问题。促进信任和团结的重要性已经告诉了参与英国政府科学咨询小组的行为科学家提供的许多建议。这一组织敦促政府了解构成英国人口的社区的多样性,并与他们进行交流、咨询、倾听和学习。此外,敦促政府支持和使人口遵守;避免指责和惩罚;在具有挑战性的情况下,经常在具有挑战性的情况下承认、奖励和庆祝成就;并以证据一致、一致和简明地沟通。最后,政府被建议在书面和口头交流中保持透明、诚实和开放;建立性别信任;避免社会分裂的语言、政策和行为。

持续的行为改变包括采取这些原则,并将其应用于创建一个相互加强的系统,在这个系统中,能力、机会和动机相互支持。要想持续提高知识水平,就需要将有关病毒传播及其预防的教育纳入各级教育计划。改善机会将需要对居住空间进行结构调整,以便在需要时更容易实现社会距离。动机的持续变化将包括社会认同的发展,更重视减少感染风险的行为,以及习惯和惯例的发展,将这些行为嵌入日常生活。上述原则是一般性的。需要详细的科学调查来开发和成功地应用它们,以创建适合不同场景的干预措施。这种干预被称为“行为、环境、社会和系统干预”(BESSIs)。尽管这些干预措施很重要,但据估计,对所有BESSI的研究投资总额不到全球用于COVID-19研究的33亿美元的4% 。

在BESSI和药理试验的对比中,对比是明显的:截至2020年12月,有1725项注册药理试验和213项进行药理试验,但只有11项注册BESSI试验和3项进行BESSI试验。

解决不平等

COVID-19大流行的一个重要教训是,任何个人、社区或国家都无法凭自己的力量保护自己:人都是相互关联的,解决方案必须是全球性的。为未来建设具有抗流行病能力的社会必须包括改变全人口的行为以及减少不平等现象。

将行为融入社会需要改变物理环境和社会环境,如培养安全的工作场所和卫生行为规范。这些需要以社区活化、组织规范和国家立法为基础。COVID-19大流行使本来就不平等的社会更加不平等,病毒在过度拥挤、多代同屋和监管不力的工作场所传播最剧烈。此外,先前有健康问题的人和来自特定种族背景的人都与贫穷有关,他们受到病毒的打击更大。

许多国家的结构性种族主义意味着,由于低收入和恶劣的工作条件,那些本来就更脆弱的人变得更加脆弱。在许多国家,政府的政策进一步加剧了不平等。在英国,有固定工资的工人比那些在不稳定的经济中工作的人在财务上得到更多的保护,抵押贷款持有人比租房者得到更好的保护。

病毒检测以及药物和疫苗将继续对应对COVID-19和未来大流行的战略至关重要。但从长远来看,对研究和项目的资金进行实质性的再平衡,以使整个社会的行为发生改变,并解决不平等问题,也将是至关重要的

原文出处

Michie, S., West, R. Sustained behavior change is key to preventing and tackling future pandemics. Nat Med (2021). https://doi.org/10.1038/s41591-021-01345-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-11-15 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2022-04-17 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-08-05 454515792

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2022-04-07 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-05-14 xugumin
  6. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-05-14 智慧医人
  8. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-05-12 易水河

    对,有所为有所不为才能解决问题

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1885142, encodeId=4bd918851422f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 15 19:37:19 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859136, encodeId=86d318591366b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 17 18:37:19 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005409, encodeId=46a91005409c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/0a263eab04264b0abfd50791eaa8a83f/b9d15bdac9f741b095d951d34834cfb5.jpg, createdBy=888c2643465, createdName=454515792, createdTime=Thu Aug 05 17:04:58 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773940, encodeId=06e31e73940b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 07 00:37:19 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411387, encodeId=e413141138e40, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577793, encodeId=92a415e7793cd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611041, encodeId=241116110416c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 14 01:37:19 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964860, encodeId=dc6396486018, content=对,有所为有所不为才能解决问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 12 11:33:09 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964851, encodeId=c8c0964851bc, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Wed May 12 11:00:19 CST 2021, time=2021-05-12, status=1, ipAttribution=)]

相关资讯

为中医药走向世界注入新的动力

世界中医药大会第四届夏季峰会在江西南昌开幕。大会以“中医药国际化新时代、新机遇、新挑战”为主题,旨在加强政策对话、促进学术创新、推动产业发展、倡导互学互鉴,为中医药走向世界注入新的动力。

Excel在临床药物动力学中的应用

于广华,李信梅  (盐城市卫生学校,江苏 盐城 224001)   临床药物动力学研中,血药浓度的计算、药动学参数的求解、给药方案的设计、数据设计及组织管理、绘制图表等,需要进行大量而繁琐的数据处理、绘制各式图形。国内药动学处理软件如3987等,图形与MS Word等字处理软件不兼容,图形也不丰富。电子表格处理系统Microsoft Excel 97 for Windows是具有强大的

Baidu
map
Baidu
map
Baidu
map